Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 天前评分90
正文 · 原文
HORIZON-Breast06:
Trastuzumab Rezetecan in HER2-Low Metastatic #BreastCancer — A Major PFS Benefit, With OS and Long-Term Safety Requiring Further Follow-Up
@OncoAlert #ESMO26 @myESMO #Bcsm
670 浏览 · 28 赞 · 11 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Aya Mohamed | MSc, MD 🎗 · x.com